Skip to content

Allotment

Anlon Healthcare Limited

Anlon Healthcare Limited is launching a book-built IPO of ₹121.03 crore, consisting entirely of a fresh issue of 1.33 crore shares at a price of ₹91 per share. The IPO bidding was open from August 26, 2025, to August 29, 2025, with allotment finalized on September 1, 2025. The shares are scheduled to list on BSE and NSE on September 3, 2025.

The IPO has a lot size of 164 shares, requiring a minimum investment of ₹14,924 for retail investors (at the upper price). Small non-institutional investors (sNII) can apply for 14 lots (2,296 shares, ₹2,08,936), while big non-institutional investors (bNII) can subscribe for 68 lots (11,152 shares, ₹10,14,832).

Interactive Financial Services Ltd. is the book-running lead manager, and Kfin Technologies Ltd. is the registrar of the issue. The IPO provides investors an opportunity to participate in Anlon Healthcare’s growth in the pharma intermediates and API manufacturing sector. For detailed information, refer to the Anlon Healthcare IPO RHP.

Anlon Healthcare Limited IPO & Charts
₹91

0%

Open

₹91

HIgh - Low

₹91

Previous Close

₹91

Total Traded Value

0

52 Weeks High

₹91

52 Weeks Low

₹91

Updates On

Aug 20, 2025

IPO. Open

Aug 26, 2026

IPO. Close

Aug 29, 2026

IPO. Price

₹91.00

IPO Market price

₹483.68 Cr

IPO Details

IPO Date 3 Sep
IPO Listing Date 3 Sep
IPO Face Value ₹10 per share
IPO Price Range ₹91.00
IPO Issue Size 1,33,00,000 shares
IPO Sale Type Fresh Capital
Employee Discount -
IPO Issue Type Bookbuilding IPO
IPO Listing BSE,NSE Platform
Share Holding Pre Issue 3,98,51,500 shares

IPO Timeline

IPO Open Date 26 Aug
IPO Close Date 29 Aug
IPO Allotment (Tentative) 1 Sep
Refunds 2 Sep
Credit to Demat Account 2 Sep
IPO Listing Date 3 Sep

IPO Reservation

Category Offer
QIB Shares Offered 99,75,000 Shares
NII (HNI) Shares Offered 19,95,000 Shares
Retail Shares Offered 13,30,000 Shares

IPO Lot Size

Investors can bid for a minimum of 164 shares, with additional shares to be purchased in multiples of 164.

Application Lots Share Amount
Retail (Min) 1 164 ₹14,924
Retail (Max) 13 2,132 ₹1,94,012
S-HNI (Min) 14 2,296 ₹2,08,936
S-HNI (Max) 67 10,988 ₹9,99,908
B-HNI (Min) 68 11,152 ₹10,14,832
About Company

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company produces high-purity intermediates for API production and APIs used in formulations for medicines, nutraceuticals, personal care, and veterinary products, adhering to Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP.

Beyond standard manufacturing, Anlon Healthcare offers custom manufacturing of complex chemicals, achieving purity levels above industry standards and minimizing impurities to meet specific customer requirements. The company has received Drug Master File (DMF) approvals from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. It has filed 21 DMFs globally and is pursuing approvals for Ketoprofen and Dexketoprofen Trometamol.

Quality is ensured through rigorous testing, analysis, and continuous process improvements. Supported by four laboratories, a 34-member team (including 24 science graduates) ensures that products meet stringent customer and regulatory standards. The company’s portfolio comprises 65 commercialized products, 28 at pilot stage, and 49 at laboratory scale testing stage.

Products:

Pharma Intermediates: Cyanoethylbenzoic acid, Ketonitrile, Methyldesloratadine, serving as key starting materials or advanced intermediates for APIs.

Active Pharmaceutical Ingredients (APIs): Core components in pharmaceuticals, used in tablets, capsules, ointments, syrups, as well as in nutraceuticals, personal care, and veterinary products.

Competitive Strengths:

Strong and scalable product portfolio

Experienced promoters and management team

High entry and exit barriers due to long customer approval cycles and strict quality standards

In-house testing, quality control, and quality assurance

Commitment to quality, environment, health, and safety

Anlon Healthcare Ltd. reported an 81% increase in revenue and a 112% rise in profit after tax (PAT) for the financial year ended March 31, 2025, compared to the year ended March 31, 2024.

Company Financials (Consolidated)

Assets 181.3 128 111.55
Total Income 120.46 66.69 113.12
Profit After Tax 20.52 9.66 5.82
EBITDA 32.38 15.57 12.66
NET Worth 80.42 21.03 7.37
Reserves and Surplus 40.57 5.03 -4.63
Total Borrowing 58.35 74.56 66.39

Key Performance Indicator (KPI)

ROE 40.45%
ROCE 21.93%
Debt/Equity 0.73
RoNW 25.51%
PAT Margin 17.06%
EBITDA Margin 26.88%
Price to Book Value 4.51
IPO Objective

IPO Objects of the Issue

S.No. Objects of the ipo Resources Detail IPO Amount
1 Funding capital expenditure requirements for the purchase of equipment/machineries -
2 To meet out the expenses of Working Capital Requirement 43.15
3 To meet out the General Corporate Purposes; 270.3
4 Offer for Sale (OFS) -

Contact Details

Anlon Healthcare Ltd. Address
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
+91 281 2562538
cs@anloncro.com

Detail Registrar

IPO Registrar

Kfin Technologies Ltd.
04067162222, 04079611000
ahl.ipo@kfintech.com

FAQ

Compare:

Back To Top